You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Thrombocythemia, Essential

Showing 1 - 25 of 4,677
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Real World Evidence of Fedratinib Effectiveness in MF

Not yet recruiting
  • Primary Myelofibrosis
  • +2 more
  • (no location specified)
May 22, 2023

Essential Thrombocytopenia Trial in Tianjin (Recombinant Interferon Alpha, Pegylated interferon alfa-2b)

Recruiting
  • Essential Thrombocytopenia
  • Recombinant Interferon Alpha
  • Pegylated interferon alfa-2b
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Jul 18, 2022

Essential Thrombocythemia Trial (Ropeginterferon alfa-2b-njft (P1101))

Not yet recruiting
  • Essential Thrombocythemia
  • Ropeginterferon alfa-2b-njft (P1101)
  • (no location specified)
Jul 28, 2022

Thrombocythemia, Essential Trial in San Antonio (IMG-7289)

Recruiting
  • Thrombocythemia, Essential
  • San Antonio, Texas
    Mays Cancer Center
Dec 14, 2021

Myeloproliferative Tumor, Polycythemia Vera, Essential Thrombocythemia Trial in Hong Kong

Recruiting
  • Myeloproliferative Neoplasm
  • +7 more
    • Hong Kong, Hong Kong
      Department of Medicine, Queen Mary Hospital
    May 21, 2023

    Polycythemia Vera, Essential Thrombocythemia, and

    Not yet recruiting
    • Myeloproliferative Neoplasm
    • Next-generation sequencing
    • (no location specified)
    Jun 27, 2022

    Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF), Post Polycythemia Vera Related Myelofibrosis (PV-MF)

    Not yet recruiting
    • Myelofibrosis (PMF)
    • +2 more
    • New York, New York
      Ruttenberg Treatment Center
    Apr 18, 2023

    Arterial Function and Atherosclerosis in Essential

    Completed
    Has Results
    • Atherosclerosis
    • imaging
    • (no location specified)
    Oct 6, 2021

    Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, ET-MF Trial in New York (Canakinumab)

    Recruiting
    • Primary Myelofibrosis
    • +4 more
    • New York, New York
      Ruttenberg Treatment Center
    Jul 18, 2022

    Myeloproliferative Tumor, MPN, Essential Thrombocythemia Trial in Orange (N-Acetylcysteine)

    Active, not recruiting
    • Myeloproliferative Neoplasm
    • +4 more
    • Orange, California
      Chao Family Comprehensive Cancer Center, University of Californi
    Jan 6, 2023

    Myeloproliferative Tumor, Essential Thrombocythemia, Primary Myelofibrosis, Prefibrotic Stage Trial (CALR allele burden

    Recruiting
    • Myeloproliferative Neoplasm
    • +3 more
    • CALR allele burden quantification
    • Angers, France
      CHU Angers
    Nov 2, 2022

    Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis

    Terminated
    • Primary Myelofibrosis (PMF)
    • +2 more
    • Larkspur, California
    • +2 more
    Nov 14, 2022

    Myelofibrosis, Essential Thrombocythemia, MPN Trial in New York (Peptide-based vaccine, Poly ICLC)

    Not yet recruiting
    • Myelofibrosis
    • +2 more
    • Peptide-based vaccine
    • Poly ICLC
    • New York, New York
      Icahn School of Medicine at Mount Sinai
    Jun 7, 2022

    The Role of Circ0014614 in the Formation and Development of ET

    Recruiting
    • Primary Thrombocytosis
      • Guangzhou, Guangdong, China
        Department of Hematology,Nanfang Hospital, Southern Medical Univ
      Jun 18, 2023

      Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis Trial in United States

      Completed
      Has Results
      • Primary Myelofibrosis
      • +2 more
      • Scottsdale, Arizona
      • +8 more
      Feb 10, 2022

      Myelodysplastic/Myeloproliferative Tumor, Unclassifiable, Myelofibrosis Transformation in Essential Thrombocythemia,

      Recruiting
      • Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
      • +3 more
      • Houston, Texas
        M D Anderson Cancer Center
      Aug 18, 2022

      Essential Thrombocythemia Trial in Worldwide (IMG-7289)

      Active, not recruiting
      • Essential Thrombocythemia
      • Jacksonville, Florida
      • +25 more
      Apr 15, 2022

      Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis Trial in Ipoh (NS-018,

      Recruiting
      • Primary Myelofibrosis
      • +2 more
      • Worcester, Massachusetts
      • +16 more
      Oct 31, 2022

      Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Secondary Myelofibrosis Trial in Houston

      Completed
      • Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
      • +2 more
      • Laboratory Biomarker Analysis
      • +2 more
      • Houston, Texas
        M D Anderson Cancer Center
      May 27, 2022

      Myelofibrosis; Anemia, Anemia, Myelofibrosis Trial in Canton, Gettysburg (DISC-0974)

      Recruiting
      • Myelofibrosis; Anemia
      • +5 more
      • Jacksonville, Florida
      • +6 more
      Jan 3, 2023

      Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis Trial in Buffalo (drug, dietary supplement, other)

      Terminated
      • Essential Thrombocythemia
      • +2 more
      • Arsenic Trioxide
      • +3 more
      • Buffalo, New York
        Roswell Park Cancer Institute
      Jul 20, 2022

      Primary Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia Trial in Toronto (Observational)

      Recruiting
      • Primary Myelofibrosis
      • +9 more
      • Observational
      • Toronto, Ontario, Canada
        Princess Margaret Cancer Centre
      Apr 11, 2022

      A Prospective, Two-arm, Non-interventional Study of JAKAVI® in

      Active, not recruiting
      • Primary Myelofibrosis
      • +2 more
      • Jakavi
      • Aachen, Germany
        Novartis Investigative Site
      Sep 6, 2021

      Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF) Trial in

      Completed
      • Myelofibrosis
      • +3 more
      • Ann Arbor, Michigan
      • +4 more
      Mar 28, 2022

      Myeloproliferative Tumor, Essential Thrombocythemia, JAK2 Mutation Trial in Ottawa (Apixaban 2.5 MG Oral Tablet [ELIQUIS],

      Recruiting
      • Myeloproliferative Neoplasm
      • +5 more
      • Apixaban 2.5 MG Oral Tablet [ELIQUIS]
      • Aspirin 81 mg
      • Ottawa, Ontario, Canada
        The Ottawa Hospital
      Apr 19, 2022